Investigational Drug Information for INCB054707
✉ Email this page to a colleague
What is the development status for investigational drug INCB054707?
INCB054707 is an investigational drug.
There have been 13 clinical trials for INCB054707.
The most recent clinical trial was a Phase 2 trial, which was initiated on November 27th 2023.
The most common disease conditions in clinical trials are Hidradenitis Suppurativa, Hidradenitis, and Vitiligo. The leading clinical trial sponsors are Incyte Corporation, Incyte Biosciences Japan GK, and [disabled in preview].
There are fifteen US patents protecting this investigational drug and two hundred and thirteen international patents.
Summary for INCB054707
US Patents | 15 |
International Patents | 213 |
US Patent Applications | 94 |
WIPO Patent Applications | 22 |
Japanese Patent Applications | 0 |
Clinical Trial Progress | Phase 2 (2023-11-27) |
Vendors | 15 |
Recent Clinical Trials for INCB054707
Title | Sponsor | Phase |
---|---|---|
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1) | Incyte Corporation | Phase 3 |
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2) | Incyte Corporation | Phase 3 |
A Study to Evaluate the Pharmacokinetics and Safety of INCB054707 in Participants With Normal Hepatic Function and Participants With Hepatic Impairment | Incyte Corporation | Phase 1 |
Clinical Trial Summary for INCB054707
Top disease conditions for INCB054707
Top clinical trial sponsors for INCB054707
US Patents for INCB054707
Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
---|---|---|---|---|
INCB054707 | ⤷ Sign Up | Bicyclic fused pyrimidine compounds as TAM inhibitors | Incyte Corporation (Wilmington, DE) | ⤷ Sign Up |
INCB054707 | ⤷ Sign Up | Pyrrolopyrimidine derivatives as TAM inhibitors | Incyte Corporation (Wilmington, DE) | ⤷ Sign Up |
INCB054707 | ⤷ Sign Up | Treatment of B-cell malignancies by a combination JAK and PI3K inhibitors | Incyte Corporation (Wilmington, DE) | ⤷ Sign Up |
INCB054707 | ⤷ Sign Up | Heterocyclic compounds as PI3K-.gamma. inhibitors | Incyte Corporation (Wilmington, DE) | ⤷ Sign Up |
INCB054707 | ⤷ Sign Up | Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors | Incyte Corporation (Wilmington, DE) | ⤷ Sign Up |
>Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for INCB054707
Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
---|---|---|---|---|
INCB054707 | World Intellectual Property Organization (WIPO) | WO2017027717 | 2035-08-12 | ⤷ Sign Up |
INCB054707 | World Intellectual Property Organization (WIPO) | WO2017035366 | 2035-08-26 | ⤷ Sign Up |
INCB054707 | Australia | AU2015244044 | 2034-04-08 | ⤷ Sign Up |
INCB054707 | Australia | AU2020213313 | 2034-04-08 | ⤷ Sign Up |
INCB054707 | Australia | AU2022206693 | 2034-04-08 | ⤷ Sign Up |
>Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |